BioNexus Stock Based Compensation from 2010 to 2026
| BGLC Stock | USD 2.28 0.08 3.64% |
Stock Based Compensation | First Reported 2010-12-31 | Previous Quarter 588.5 K | Current Value 617.9 K | Quarterly Volatility 244.9 K |
Check BioNexus Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNexus Gene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 184.9 K, Interest Expense of 25.5 K or Other Operating Expenses of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.57. BioNexus financial statements analysis is a perfect complement when working with BioNexus Gene Valuation or Volatility modules.
BioNexus | Stock Based Compensation | Build AI portfolio with BioNexus Stock |
Analyzing BioNexus Gene's Stock Based Compensation over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Stock Based Compensation has evolved provides context for assessing BioNexus Gene's current valuation and future prospects.
Latest BioNexus Gene's Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of BioNexus Gene Lab over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. BioNexus Gene's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNexus Gene's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
BioNexus Stock Based Compensation Regression Statistics
| Arithmetic Mean | 131,171 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 186.68 | |
| Mean Deviation | 200,614 | |
| Median | 0.00 | |
| Standard Deviation | 244,875 | |
| Sample Variance | 60B | |
| Range | 617.9K | |
| R-Value | 0.74 | |
| Mean Square Error | 28.7B | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | 36,010 | |
| Total Sum of Squares | 959.4B |
BioNexus Stock Based Compensation History
Other Fundumenentals of BioNexus Gene Lab
BioNexus Gene Stock Based Compensation component correlations
Click cells to compare fundamentals
About BioNexus Gene Financial Statements
BioNexus Gene stakeholders use historical fundamental indicators, such as BioNexus Gene's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although BioNexus Gene investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioNexus Gene's assets and liabilities are reflected in the revenues and expenses on BioNexus Gene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioNexus Gene Lab. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 588.5 K | 617.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out the analysis of BioNexus Gene Correlation against competitors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Will Specialty Chemicals sector continue expanding? Could BioNexus diversify its offerings? Factors like these will boost the valuation of BioNexus Gene. Projected growth potential of BioNexus fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BioNexus Gene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.95) | Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioNexus Gene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioNexus Gene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioNexus Gene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.